Depomed Names Vice President of Marketing
MENLO PARK, CA: Depomed, Inc. announced today that Kevin Weber will join the company as Vice President of Marketing effective July 5, 2011. Mr. Weber will lead all marketing activities for the company including the launch of GraliseTM (gabapentin), its once-daily formulation of gabapentin for the management of postherpetic neuralgia. He will also provide commercial guidance to future products, including strategic product selection and commercial development.
“We are pleased Kevin has agreed to join the Depomed team. He has over 25 years of experience in commercializing pharmaceutical products and successfully executing marketing campaigns,” said James A. Schoeneck, president and chief executive officer of Depomed. “Kevin is experienced in building and leading teams in pressure-laden environments and achieving critical business objectives. Together with our vice president of sales, Steve Greco, we have the commercial leadership in place now to execute a high quality launch of Gralise.”
Mr. Weber has over 25 years of experience in pharmaceutical marketing and operations. Until 2007, he was at Medicis Pharmaceuticals for 8 years, most recently as Vice President, Division Head of Ucyclyd Pharmaceuticals, where he was responsible for the orphan drug division and instrumental in growing Medicis’ sales to over $440 million in 2007 from $87 million in 1999. Since 2007, Mr. Weber was Senior Vice President, Global Operations and Strategy at Hyperion Therapeutics, a Biotech focused on orphan diseases and President of BioMark Partners, a strategic marketing consulting firm. Mr. Weber started his career at Rhone-Poulenc Rorer Pharmaceuticals in 1985 and spent 12 years in marketing and product management roles there, most recently as US Marketing Director Asthma. Mr. Weber holds a Bachelor of Business Administration from Western Michigan University.
Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and another recently approved product. GraliseTM (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. The company also has a robust pipeline including Serada®, which is in Phase 3 clinical development for menopausal hot flashes, as well as earlier stage candidates. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, http://www.depomed.com.
Media contact: Sheilah Serradell